Janssen Pharmaceutica Nv

3-dimensional Pharmaceuticals, Inc.

Bristol-myers Squibb Compnay

Kenneth Jerome Wilson

Carl R Illig

Jinsheng Chen

Sanath K Meegalla

Mark James Wall

Renee Louise Desjarlais

Shelley K Ballentine

M Jonathan Rudolph

Nalin L Subasinghe

James B Hoffman

Christopher J Molloy

Mark R Player

Roger Francis Bone

Daniel J Parks

Hui Huang

Yu-Kai Lee

Juan Jos&eacute; Marug&aacute;n

Troy L Randle

Carl M Manthey

Scott L Klein

Tianbao Lu

Mark E Salvati

Christopher M Flores

Christopher A Teleha

Raymond Joseph Patch

Jean-Pierre André Marc Bongartz

Alfred Elisabeth Stappers

Renee L DesJarlais

Carl L Manthey

Wing S Cheung

Sharmila Patel

Koen Johan Herman Weerts

Shelly K Ballentine

Jonathan Rudolph

A method of reducing or inhibiting kinase activity of C-KIT in a cell or a subject, and the use of such compounds for preventing or treating in a subject a cell proliferative disorder and/or disorders related to C-KIT using a compound of the present invention: or a solvate, hydrate, tautomer or pharmaceutically acceptable salt thereof. The present invention is further directed to methods for treating conditions such as cancers and other cell proliferative disorders.

Method of inhibiting C-KIT kinase

The invention is directed to compounds of Formula I: wherein Z, X, J, Rand W are set forth in the specification, as well as solvates, hydrates, tautomers and pharmaceutically acceptable salts thereof, that inhibit protein tyrosine kinases, especially c-fms kinase. Methods of treating autoimmune diseases; and diseases with an inflammatory component; treating metastasis from ovarian cancer, uterine cancer, breast cancer, colon cancer, stomach cancer, hairy cell leukemia and non-small lung carcinoma; and treating pain, including skeletal pain caused by tumor metastasis or osteoarthritis, or visceral, inflammatory, and neurogenic pain; as well as osteoporosis, Paget's disease, and other diseases in which bone resorption mediates morbidity including arthritis, prosthesis failure, osteolytic sarcoma, myeloma, and tumor metastasis to bone with the compounds of Formula I, are also provided.

Inhibitors of c-fms kinase

The invention is directed to compounds of Formula I: wherein Z, X, J, Rand W are set forth in the specification, as well as solvates, hydrates, tautomers and pharmaceutically acceptable salts thereof, that inhibit protein tyrosine kinases, especially c-fms kinase. Methods of treating autoimmune diseases; and diseases with an inflammatory component; treating metastasis from ovarian cancer, uterine cancer, breast cancer, prostate cancer, lung cancer, colon cancer, stomach cancer, hairy cell leukemia; and treating pain, including skeletal pain caused by tumor metastasis or osteoarthritis, or visceral, inflammatory, and neurogenic pain; as well as osteoporosis, Paget's disease, and other diseases in which bone resorption mediates morbidity including rheumatoid arthritis, and other forms of inflammatory arthritis, osteoarthritis, prosthesis failure, osteolytic sarcoma, myeloma, and tumor metastasis to bone with the compounds of Formula I, are also provided.

The present invention is directed to a process for the preparation of heterocyclic ester derivatives of formula I wherein A, SEM, and Ware as defined herein. Such compounds are useful as intermediates in the synthesis of derivatives useful as protein tyrosine kinase inhibitors, more particularly inhibitors of c-fms kinase.

Process for the preparation of heterocyclic ester derivatives

Inhibitors of C-FMS kinase

Disclosed are compounds, compositions and methods for treating Type II diabetes and other disorders affected by activity of the enzyme PDE10a. Such compounds are represented by Formula (I) below, wherein R, R, L and Q are defined herein. 

PDE10a inhibitors for the treatment of type II diabetes

Disclosed are compounds, compositions and methods for treating Type II diabetes. Such compounds are represented by Formula (I) as follows: wherein R, R, L, and Q are defined herein.

PDE 10a inhibitors for the treatment of type II diabetes

The invention is directed to compounds of Formula I: 

The invention relates to arylamide and hetereoarylamide compounds of Formula I: wherein A, X, Rand W are set forth in the specification, as well as tautomers and pharmaceutically acceptable salts thereof, that inhibit protein tyrosine kinases, especially c-fms kinase. Methods of treating autoimmune diseases; and diseases with an inflammatory component; treating metastasis from ovarian cancer, uterine cancer, breast cancer, colon cancer, stomach cancer, hairy cell leukemia and non-small lung carcinoma; and treating pain, including skeletal pain caused by tumor metastasis or osteoarthritis, or visceral, inflammatory, and neurogenic pain; as well as osteoporosis, Paget's disease, and other diseases in which bone resorption mediates morbidity including arthritis, prosthesis failure, osteolytic sarcoma, myeloma, and tumor metastasis to bone with the compounds of Formula I, are also provided.

Class of arylamide compounds useful as inhibitors of c-fms kinase

Disclosed are pyrrolopyridazine compounds of the formula,wherein the substituents are defined herein,methods of preparing such compounds, and their use for the treatment of proliferative, inflammatory, and other disorders.

Pyrrolopyridazine compounds and methods of use thereof for the treatment of proliferative disorders

Heteroaryl amidines, methylamidines and guanidines, and the use thereof as protease inhibitors

Growing community of inventors

Playas Del Coco, Costa Rica

Kenneth Jerome Wilson